Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial

Journal of Cellular Biochemistry

Volumn 77, Issue SUPPL. 34, 2000, Pages 73-79

  Formelli, Franca ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

4 HPR; breast cancer; Circulating surrogate endpoint biomarkers; Prevention

Indexed keywords

FENRETINIDE; RETINOL; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; ANTINEOPLASTIC AGENT; PLASMINOGEN ACTIVATOR; PROTEIN P53; TUMOR MARKER;

BREAST CANCER; CANCER INCIDENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; ARTICLE; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; CLINICAL TRIAL; EVALUATION; FEMALE; IMMUNOLOGY; METABOLISM; METHODOLOGY; PREDICTION AND FORECASTING; REPRODUCIBILITY; STANDARD;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS; EVALUATION STUDIES; FEMALE; FENRETINIDE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PLASMINOGEN ACTIVATORS; PREDICTIVE VALUE OF TESTS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VITAMIN A;

EID: 0033649561     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(2000)77:34+<73::AID-JCB13>3.0.CO;2-H     Document Type: Review

References (17)

1. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. 1993. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206.
2. Basu TK, Sasmal P. 1988. Plasma vitamin A, retinol-binding protein, and prealbumin in postoperative breast cancer patients. Int J Vit Nutr Res 58:281-283.
3. Cobleigh MA, Dowlatshahi K, Deutsch TA, Mehta RG, Moon RC, Minn F, Benson AB, Rademaker AW, Ashenhurst JB, Wade JL. 1993. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 11: 474-477.
4. Crawford LV, Pim DC, Bulbrook RD. 1982. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 15:403-408.
5. Decensi A, Torrisi R, Polizzi A, Gesi R, Brezzo V, Rolando M, Rondanina G, Orengo MA, Formelli F, Costa A. 1994. Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface. J Natl Cancer Inst 86:105-110.
6. De Palo G, Camerini T, Marubini E, Costa A, Formelli F, Del Vecchio M, Mariani L, Miceli R, Mascotti G, Magni A, Campa T, Di Mauro MG, Attili A, Maltoni C, Del Turco MR, Decensi A, D'Aiuto G, Veronesi U. 1997. Chemopre vention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori 83:884-894.
7. Duffy MJ, O'Grady P, Devancy D, O'Siorain L, Fennelly JJ, Lijnen HR. 1988. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 48:1348-1349.
8. Duffy MJ, Reilly D, O'Sullivan C, O'Hoggins N, Fennelly JJ, Andreasen P. 1990. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50:6827-6829.
9. Elledge RM, Allred DC. 1994. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 32:39-47.
10. Formelli F, Carsana R, Costa A, Buranelli F, Campa T, Dossena G, Magni A, Pizzichetta M. 1989. Plasma retinol level reduction by the synthetic retinoid fenretinide: A one year follow-up study of breast cancer patients. Cancer Res 48:6149-6152.
11. Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, Mascotti G, Moglia D, De Palo G, Costa A, Veronesi U. 1993. Five-year administration of fenretinide: Pharmacokinetic and effects on plasma retinol concentrations. J Clin Oncol 11:2036-2042.
12. Formelli F, Cleris L, Cavadini E, Camerini T, Di Mauro MG, Campa T, Magni A, Costa A, De Palo G, Veronesi U. 1996. Analysis of fenretinide (4HPR) effects on plasma IGF-1 levels in relation with age and chemopreventive efficacy in breast cancer patients. Proc Am Assn Cancer Res 37:185.
13. Green JA, Mudenda B, Jenkins J, Leinster SJ, Tarunina M, Green B, Rohertson L. 1994. Serum p53 auto-antibodies: Incidence in familial breast cancer. Eur J Cancer 30:580-584.
14. Grondahl-Hansen J, Bach F, Munkholm-Larsen P. 1990. Tissue-type plasminogen activator in plasma from breast cancer patients determined by enzyme-linked immunosorbent assay. Br J Cancer 61:412-414.
15. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. 1998. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396.
16. Kooistra T, Opdenberg JP, Toet K, Hendriks HF, van den Hoogen RM, Emeis JJ. 1991. Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo. Thromb Hemostasis 65:565-572.
17. Mannucci PM, Cugno M, Bottasso B, Marongiu F, Maniezzo M, Vaglini M, Cascinelli N. 1990. Changes in fibrinolysis in patients with localized tumors. Eur J Cancer 26:83-87.